Mannose as a biomarker of coronary artery disease : Angiographic evidence and clinical significance
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND: High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease (CAD).
METHODS: Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomography angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on subsequent CVD events/death was collected. Associations of mannose with angiographic variables and biomarkers were tested using univariate and multivariate regression models. Survival analysis was performed using the Kaplan-Meier estimator.
RESULTS: Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose change [95% confidence interval, 1.05-1.65]) and was an independent predictor of death (hazard ratio for mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4-11.3), p = 0.006).
CONCLUSION: The current data add novel evidence that high mannose is a signature of CAD with a vulnerable plaque phenotype, consistently across measures of severity of vessel involvement and independent of the traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:346 |
|---|---|
| Enthalten in: |
International journal of cardiology - 346(2022) vom: 01. Jan., Seite 86-92 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrannini, Ele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 26.01.2022 Date Revised 26.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijcard.2021.11.038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333379381 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333379381 | ||
| 003 | DE-627 | ||
| 005 | 20231225221537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2021.11.038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333379381 | ||
| 035 | |a (NLM)34800594 | ||
| 035 | |a (PII)S0167-5273(21)01855-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrannini, Ele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mannose as a biomarker of coronary artery disease |b Angiographic evidence and clinical significance |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2022 | ||
| 500 | |a Date Revised 26.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease (CAD) | ||
| 520 | |a METHODS: Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomography angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on subsequent CVD events/death was collected. Associations of mannose with angiographic variables and biomarkers were tested using univariate and multivariate regression models. Survival analysis was performed using the Kaplan-Meier estimator | ||
| 520 | |a RESULTS: Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose change [95% confidence interval, 1.05-1.65]) and was an independent predictor of death (hazard ratio for mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4-11.3), p = 0.006) | ||
| 520 | |a CONCLUSION: The current data add novel evidence that high mannose is a signature of CAD with a vulnerable plaque phenotype, consistently across measures of severity of vessel involvement and independent of the traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Computed coronary tomography angiography | |
| 650 | 4 | |a Coronary angiography | |
| 650 | 4 | |a Coronary atherosclerosis | |
| 650 | 4 | |a Optical coherence tomography | |
| 650 | 4 | |a Plasma mannose | |
| 650 | 4 | |a Risk assessment | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Mannose |2 NLM | |
| 650 | 7 | |a PHA4727WTP |2 NLM | |
| 700 | 1 | |a Marx, Nikolaus |e verfasserin |4 aut | |
| 700 | 1 | |a Andreini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Campi, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Saba, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Gorini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrannini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Milzi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Magnoni, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Maseri, Attilio |e verfasserin |4 aut | |
| 700 | 1 | |a Maggioni, Aldo P |e verfasserin |4 aut | |
| 700 | 1 | |a Burgmaier, Mathias |e verfasserin |4 aut | |
| 700 | 0 | |a CAPIRE investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 346(2022) vom: 01. Jan., Seite 86-92 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
| 773 | 1 | 8 | |g volume:346 |g year:2022 |g day:01 |g month:01 |g pages:86-92 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijcard.2021.11.038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 346 |j 2022 |b 01 |c 01 |h 86-92 | ||